FTC challenges ‘junk’ drug patents. Here’s what they are and why they matter
The US Federal Trade Commission (FTC) announced last week that, for the second time, dispute hundreds of rubbish patents listed in the Food and Drug Administrations (FDA) Orange Book, a …